-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Junshi Biotech announced that the company plans to issue A shares to specific targets.
The issuance plans to raise no more than 3.
98 billion yuan and issue no more than 70 million shares, which will be used for innovative drug research and development projects and Shanghai Junshi.
Biotechnology headquarters and R&D base projects
.
Specifically, 3.
682 billion yuan will be invested in innovative drug research and development projects.
The main research directions include 20 clinical research and development projects including JS001 follow-up domestic and overseas clinical research and development, as well as preclinical research on other early projects.
The project is expected to be implemented for a period of 3 years
.
In addition, the remaining 298 million yuan will be allocated to the Shanghai Junshi Biotechnology headquarters and R&D base projects, and will also be used to meet the research and development needs of innovative drugs in the pre-clinical stage and the office needs of personnel involved in clinical research
.
It is understood that in addition to this fund-raising increase in innovative drugs, Junshi Bio has been increasing investment in research and development in recent years
.
In 2021, the third quarterly report shows that Junshi Bio's research and development expenses have reached 1.
432 billion yuan, a year-on-year increase of 17.
56%.
In contrast, its sales expenses are only 527 million yuan
.
Industry analysts believe that innovation has clearly become one of the core competitiveness in the field of medicine in recent years
.
In addition to Junshi Bio, many pharmaceutical companies are currently increasing investment in the research and development of innovative drugs
.
For example, Jiangsu Quanxin Bio-Pharmaceutical Co.
, Ltd.
(hereinafter referred to as Quanxin Bio-Pharmaceutical or the company) has also successfully completed hundreds of millions of C rounds of financing
.
According to the data, Jiangsu Quanxin Bio-Pharmaceutical Co.
, Ltd.
is a technology-driven antibody innovative drug research and development enterprise.
In response to the unmet clinical needs in the field of autoimmune and allergic diseases, Quanxin Bio has been focusing on the layout
.
Up to now, the company has 6 products in the clinical stage.
Among them, QX001S, developed in cooperation with Huadong Medicine, has completed the enrollment of all subjects in Phase 3 clinical trials.
Phase 1 and Phase 2 clinical trials were expanded on a total of 6 indications such as spondylitis and atopic dermatitis; its holding production base, Safes, successfully obtained the "Drug Production License" and successfully completed the commercialization of multiple batches of 2000L.
Production of stock solutions and corresponding preparations
.
On the whole, many pharmaceutical companies have increased their research and development of innovative drugs, which actually means that China's innovative drug industry is booming
.
According to data, under the background of the continuous improvement of China's innovative drug industry, more and more achievements have begun to emerge
.
For example, the number of new drug clinical trials in China has continued to grow since 2016
.
Among them, as of November 2019, 2020, and 2021, the number of Phase I clinical projects increased by 118, 54, and 172, respectively
.
In addition, according to statistics, the number of Class I new drugs listed in China from 2018 to 2021 is also more than 10, of which 26 are in 2021
.
In 2022, the industry expects that a large number of domestic innovative drugs will gradually usher in the harvest period
.
With the advancement of the research and development of innovative drugs in China, the industry generally believes that domestic new drugs will provide more new options for patients
.
It is understood that in fact, on March 1, the new indication of the first monoclonal antibody drug Hanlikang (rituximab injection) independently developed by Zhangjiang pharmaceutical company Fuhong Henlius has been approved by the State Drug Administration.
The combination of aminopterin is used for adult patients with moderately to severely active rheumatoid arthritis (RA) who are ineffective against one or more TNF-α inhibitors, providing a new medication option for patients with autoimmune diseases
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The issuance plans to raise no more than 3.
98 billion yuan and issue no more than 70 million shares, which will be used for innovative drug research and development projects and Shanghai Junshi.
Biotechnology headquarters and R&D base projects
.
Specifically, 3.
682 billion yuan will be invested in innovative drug research and development projects.
The main research directions include 20 clinical research and development projects including JS001 follow-up domestic and overseas clinical research and development, as well as preclinical research on other early projects.
The project is expected to be implemented for a period of 3 years
.
In addition, the remaining 298 million yuan will be allocated to the Shanghai Junshi Biotechnology headquarters and R&D base projects, and will also be used to meet the research and development needs of innovative drugs in the pre-clinical stage and the office needs of personnel involved in clinical research
.
It is understood that in addition to this fund-raising increase in innovative drugs, Junshi Bio has been increasing investment in research and development in recent years
.
In 2021, the third quarterly report shows that Junshi Bio's research and development expenses have reached 1.
432 billion yuan, a year-on-year increase of 17.
56%.
In contrast, its sales expenses are only 527 million yuan
.
Industry analysts believe that innovation has clearly become one of the core competitiveness in the field of medicine in recent years
.
In addition to Junshi Bio, many pharmaceutical companies are currently increasing investment in the research and development of innovative drugs
.
For example, Jiangsu Quanxin Bio-Pharmaceutical Co.
, Ltd.
(hereinafter referred to as Quanxin Bio-Pharmaceutical or the company) has also successfully completed hundreds of millions of C rounds of financing
.
According to the data, Jiangsu Quanxin Bio-Pharmaceutical Co.
, Ltd.
is a technology-driven antibody innovative drug research and development enterprise.
In response to the unmet clinical needs in the field of autoimmune and allergic diseases, Quanxin Bio has been focusing on the layout
.
Up to now, the company has 6 products in the clinical stage.
Among them, QX001S, developed in cooperation with Huadong Medicine, has completed the enrollment of all subjects in Phase 3 clinical trials.
Phase 1 and Phase 2 clinical trials were expanded on a total of 6 indications such as spondylitis and atopic dermatitis; its holding production base, Safes, successfully obtained the "Drug Production License" and successfully completed the commercialization of multiple batches of 2000L.
Production of stock solutions and corresponding preparations
.
On the whole, many pharmaceutical companies have increased their research and development of innovative drugs, which actually means that China's innovative drug industry is booming
.
According to data, under the background of the continuous improvement of China's innovative drug industry, more and more achievements have begun to emerge
.
For example, the number of new drug clinical trials in China has continued to grow since 2016
.
Among them, as of November 2019, 2020, and 2021, the number of Phase I clinical projects increased by 118, 54, and 172, respectively
.
In addition, according to statistics, the number of Class I new drugs listed in China from 2018 to 2021 is also more than 10, of which 26 are in 2021
.
In 2022, the industry expects that a large number of domestic innovative drugs will gradually usher in the harvest period
.
With the advancement of the research and development of innovative drugs in China, the industry generally believes that domestic new drugs will provide more new options for patients
.
It is understood that in fact, on March 1, the new indication of the first monoclonal antibody drug Hanlikang (rituximab injection) independently developed by Zhangjiang pharmaceutical company Fuhong Henlius has been approved by the State Drug Administration.
The combination of aminopterin is used for adult patients with moderately to severely active rheumatoid arthritis (RA) who are ineffective against one or more TNF-α inhibitors, providing a new medication option for patients with autoimmune diseases
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
